Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
Iovance (NASDAQ: IOVA) approved inducement stock options on April 16, 2026 covering 135,470 shares granted to twelve new non-executive employees under its Amended and Restated 2021 Inducement Plan. Each option has an exercise price of $3.80 (closing price on the Date of Grant) and vests over three years.
Vesting: one-third on the first anniversary of each employee’s start date, then eight quarterly installments over the following two years, subject to continued employment.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – IOVA
On the day this news was published, IOVA declined 2.07%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
IOVA was down 0.52% while peers were mixed: SANA (-1.12%), EYPT (-0.47%), NKTR (-0.16%), IMNM (+3.27%), URGN (+2.36%). Moves do not indicate a unified sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 20 | Inducement grants | Neutral | -1.6% | Small inducement stock option grant to one new non-executive employee. |
| Feb 26 | Conference participation | Neutral | -1.0% | Management scheduled presentations at two March 2026 healthcare conferences. |
| Feb 24 | Clinical trial data | Positive | +30.8% | Early lifileucel data in sarcomas showed 50% confirmed objective response rate. |
| Feb 24 | Earnings and updates | Positive | +30.8% | Reported strong 2025 revenue, margin improvement and regulatory/pipeline progress. |
| Feb 20 | Inducement grants | Neutral | +0.7% | Inducement stock options for two new employees under existing inducement plan. |
Large positive reactions followed major clinical and earnings updates (+30.8%), while routine items like inducement grants and conference notices saw small, mixed moves.
Over recent months, Iovance combined strong fundamentals with advancing clinical programs. On Feb 24, 2026, it reported positive soft tissue sarcoma TIL data and strong 2025 results, each linked to a +30.8% move. Routine inducement grant press releases on Feb 20 and Mar 20, 2026 involved small option awards and corresponded to modest price changes. A conference participation update on Feb 26, 2026 also saw a limited reaction. Today’s larger inducement grants fit this pattern of operational housekeeping news.
Market Pulse Summary
This announcement details standard inducement stock option grants to new non-executive employees at an exercise price of $3.80, vesting over three years under the 2021 Inducement Plan. In recent history, Iovance’s share price reacted most strongly to substantive clinical outcomes and earnings, including +30.8% moves around positive TIL data and strong 2025 results. Investors monitoring this update may focus more on future clinical trial readouts, commercial performance, and any changes highlighted in upcoming proxy and regulatory filings.
Key Terms
inducement stock options financial
nasdaq listing rule 5635(c)(4) regulatory
exercise price financial
vesting financial
AI-generated analysis. Not financial advice.
SAN CARLOS, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on April 16, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 135,470 shares of Iovance’s common stock to twelve new, non-executive employees.
The awards were granted under Iovance’s Amended and Restated 2021 Inducement Plan, which was adopted on September 22, 2021 and amended and restated on January 12, 2022, March 13, 2023, February 26, 2024, and November 22, 2024, and provides for the granting of equity awards to new employees of Iovance by the Company’s compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4). Each of the stock options granted as referenced in this press release has an exercise price of
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance’s Amtagvi® is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit www.iovance.com.
Amtagvi® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.
Forward-Looking Statements
Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
CONTACTS
Investors
IR@iovance.com
650-260-7120 ext. 150
Media
PR@iovance.com
650-260-7120 ext. 150
